Citeline Podcasts

Quick Listen: Scrip's Five Must-Know Things

https://scrip.pharmaintelligence.informa.com/SC147398/Quick-Listen-Scrips-Five-MustKnow-Things

Suzhou and Boston-based Harbour BioMed recently shifted strategy, divesting its site in Suzhou to WuXi in a bid to be “more focused, efficient and nimble” to emerge stronger post-pandemic, says the company founder, chairman and CEO Jinsong Wang in an extensive interview.

US-based Vaxxinity Inc’s co-founder and CEO Mei Mei Hu and her team are developing peptide-based vaccines to treat or prevent chronic illnesses like cardiovascular disease and infectious ones like COVID-19. Scrip spoke to her on when data readouts from these immunotherapeutic candidates can be expected and her plans to make them accessible. Whether or not UB-313 will prove to be the first choice to prevent migraines and VXX-401, a vaccine to prevent hypercholesterolemia, will be cheaper than statins, only time will tell. But Hu and her team are trying.

レポート『臨床試験を牽引するアジア太平洋地域～Asia Pacific as a Clinical Trials Powerhouse（2022年10月発行）』を要約し、短い音声ファイルにまとめました。臨床試験データベース「Trialtrove」のデータを基に、2012年から2021年の10年間におけるAPAC（アジア太平洋地域）の臨床試験状況を分析しています。

フルレポートをお読みになりたい方は、下記のURLからダウンロードしてください。APACにおける治験依頼者、対象疾患、試験の種類などについても詳しく解説しています。

【日本語版】

https://images.intelligence.informa.com/Web/InformaUKLimited/%7Bc5d2830a-4459-414d-ae16-795bbaba8aaf%7D_J202012-0049-21_APAC_paper_final_ORIGINAL_rev1012_JP.pdf

【英語版】

https://images.intelligence.informa.com/Web/InformaUKLimited/%7B5aa69e1c-6980-44db-94f8-6b82f411e712%7D_Asia_Pacific_Clinical_Trials_Powerhouse_Whitepaper_FINAL_EN.pdf

★臨床試験データベース「Trialtrove」

https://pharmaintelligence.informa.com/ja-JP/products-and-services/clinical-planning/trialtrove

머크가 400억달러 규모의 씨젠 인수에서 손을 떼는 등 빅파마들이 여전히 인수합병에 나서는 것을 자제하고 있다는 Scrip 기사를 요약한 내용입니다.

https://scrip.pharmaintelligence.informa.com/SC147191/Pfizer-Leads-Big-Pharma-MA-In-2022--But-Is-There-More-To-Come

Pink Sheet reporters and editor discuss the impact of the midterm elections on the US Food and Drug Administration, the Inflation Reduction Act’s effects on drug development, and adjustments to the FDA’s expanded access guidance.

Accenture's Petra Jantzer on M&A trends and what it means for execs by Citeline

https://scrip.pharmaintelligence.informa.com/SC147319/Quick-Listen-Scrips-Five-MustKnow-Things

International Vaccine Institute Director General Jerome Kim talks about what role IVI has been playing in Korea’s vaccine strategy, what makes the country an ideal place for a global vaccine hub and why this is significant for the country.

https://scrip.pharmaintelligence.informa.com/SC147314/How-IVI-Is-Helping-To-Shape-Koreas-Vaccine-Ambitions

In this edition of the Medtech Monthly podcast, Medtech Insight editor Reed Miller talks to UK-based reporter Barnaby Pickering to get a update on the state of diabetes tech and future of this dynamic market.

Articles reference in this podcast include:

Bigfoot Looks To Unlock More Effective Treatments For Type II Diabetics

https://medtech.pharmaintelligence.informa.com/MT145973/Bigfoot-Looks-To-Unlock-More-Effective-Treatments-For-Type-II-Diabetics

Dexcom’s G7 Expands Globally After A Long Wait

https://medtech.pharmaintelligence.informa.com/MT145894/Dexcoms-G7-Expands-Globally-After-A-Long-Wait

Minute Insight: Indigo Diabetes Starts Human Trial Of Subcutaneous Glucose Monitor

https://medtech.pharmaintelligence.informa.com/MT145875/Minute-Insight-Indigo-Diabetes-Starts-Human-Trial-Of-Subcutaneous-Glucose-Monitor

Class-Action Suit Alleges Medtronic’s Rosy Forecast For MiniMed780G Misled Investors

https://medtech.pharmaintelligence.informa.com/MT145828/Class-Action-Suit-Alleges-Medtronics-Rosy-Forecast-For-MiniMed780G-Misled-Investors

Published ADAPT Results Further Support Medtronic’s Highly Anticipated 780G

https://medtech.pharmaintelligence.informa.com/MT145803/Published-ADAPT-Results-Further-Support-Medtronics-Highly-Anticipated-780G

Insulet Receives FDA Clearance For Omnipod For Children Ages 2 And Up

https://medtech.pharmaintelligence.informa.com/MT145733/Insulet-Receives-FDA-Clearance-For-Omnipod-For-Children-Ages-2-And-Up

Medtech Monthly, Ep. 2: Where Does Diabetes Tech Stand In 2022?

https://medtech.pharmaintelligence.informa.com/MT145676/Medtech-Monthly-Ep-2-Where-Does-Diabetes-Tech-Stand-In-2022

Relevant Meddevicetracker market reports:

Diabetes Management: Insulin Pumps Market

https://www.meddevicetracker.com/ReportDetail.cfm?ReportID=503

Diabetes Management: Blood Glucose Monitoring Devices Market

https://www.meddevicetracker.com/ReportDetail.cfm?ReportID=463

Digital Health: Diabetes Apps and Virtual Coaching

https://www.meddevicetracker.com/ReportDetail.cfm?ReportID=439